HK-based Chi-Med doses first patient in China PhII thyroid cancer trial of sulfatinib

Hong Kong-based Hutchinson China MediTech, or Chi-Med, has moved into an open-label Phase II clinical trial in thyroid cancer with candidate HMPL-012, sulfatinib, in China, building on other oncology efforts that include a U.S. Phase I clinical trial to treat neuroendocrine tumors.

Chi-Med CEO Christian Hogg

The company said in a release that it dosed the first patient on March 1, with the study to evaluate the efficacy and safety focused on patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer, or medullary thyroid cancer.

The full trial to evaluate efficacy and safety will enroll around a total of 50 patients in both categories split evenly, the release said in a two-stage design that will see 15 patients apiece with each tumor type in a first stage.

The remaining 10 patients for each tumor type will be enrolled after efficacy assessment in the second stage.

The company said it "believes that sulfatinib's VEGFR/FGFR1 inhibition profile has strong potential in second-line thyroid cancer patients, particularly in China where there are few safe and effective treatment options for this patient population."

Now listed in London, Chi-Med, part of Li Ka-shing-controlled CK Hutchison Holdings, announced its intention in October to list on the Nasdaq and in In February filed an amended F-1 form with the U.S. Securities and Exchange Commission for the planned $100 million IPO in which it plans to sell American depositary shares (ADSs) under the symbol HCM.

On March 1, the company again filed an F-1 to include the audited consolidated financial results of Chi-Med for the year ended Dec. 31, 2015.

The company is focused on oncology and immunological diseases with 7 clinical-stage drug candidates in its pipeline, 5 of which already having "achieved proof-of-concept" that could see them become "eligible for accelerated approval by the U.S. Food and Drug Administration. It owns four of the candidates and has partnerships on the others with AstraZeneca ($AZN), Eli Lilly ($LLY) and Nestle Health Science.

- here's the release
- and the outline of the trial from

Suggested Articles

CureVac was granted a patent by the U.S. Patent and Trademark Office for its manufacturing process for producing RNA.

The WHO stopped classifying Zika as an emergency in late 2016, but Takeda has pressed ahead with its program, winning an FDA fast-track designation.

After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.